Arcus Biosciences, Inc. (RCUS)
NYSE: RCUS · Real-Time Price · USD
25.45
+0.19 (0.75%)
At close: Dec 5, 2025, 4:00 PM EST
25.97
+0.52 (2.04%)
After-hours: Dec 5, 2025, 7:54 PM EST
Arcus Biosciences Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Revenue | 240 | 258 | 117 | 112 | 383 | 78 | |
| Revenue Growth (YoY) | -8.74% | 120.51% | 4.46% | -70.76% | 391.03% | 420.00% | |
| Cost of Revenue | 503 | 448 | 340 | 288 | 257 | 159 | |
| Gross Profit | -263 | -190 | -223 | -176 | 126 | -81 | |
| Selling, General & Admin | 112 | 120 | 117 | 104 | 72 | 43 | |
| Operating Expenses | 112 | 120 | 117 | 104 | 72 | 43 | |
| Operating Income | -375 | -310 | -340 | -280 | 54 | -124 | |
| Interest Expense | -8 | -4 | -2 | -2 | - | - | |
| Interest & Investment Income | 43 | 52 | 41 | 16 | 1 | 1 | |
| EBT Excluding Unusual Items | -340 | -262 | -301 | -266 | 55 | -123 | |
| Asset Writedown | - | -20 | - | - | - | - | |
| Pretax Income | -340 | -282 | -301 | -266 | 55 | -123 | |
| Income Tax Expense | 1 | 1 | 6 | 1 | 2 | - | |
| Net Income | -341 | -283 | -307 | -267 | 53 | -123 | |
| Net Income to Common | -341 | -283 | -307 | -267 | 53 | -123 | |
| Shares Outstanding (Basic) | 101 | 90 | 74 | 72 | 69 | 55 | |
| Shares Outstanding (Diluted) | 101 | 90 | 74 | 72 | 74 | 55 | |
| Shares Change (YoY) | 17.06% | 21.76% | 2.78% | -2.70% | 35.04% | 25.04% | |
| EPS (Basic) | -3.39 | -3.14 | -4.15 | -3.71 | 0.76 | -2.24 | |
| EPS (Diluted) | -3.39 | -3.14 | -4.15 | -3.71 | 0.71 | -2.24 | |
| Free Cash Flow | -464 | -176 | -330 | 432 | -282 | 108 | |
| Free Cash Flow Per Share | -4.61 | -1.95 | -4.46 | 6.00 | -3.81 | 1.97 | |
| Gross Margin | -109.58% | -73.64% | -190.60% | -157.14% | 32.90% | -103.85% | |
| Operating Margin | -156.25% | -120.15% | -290.60% | -250.00% | 14.10% | -158.97% | |
| Profit Margin | -142.08% | -109.69% | -262.39% | -238.39% | 13.84% | -157.69% | |
| Free Cash Flow Margin | -193.33% | -68.22% | -282.05% | 385.71% | -73.63% | 138.46% | |
| EBITDA | -365 | -300 | -332 | -274 | 58 | -121 | |
| EBITDA Margin | -152.08% | -116.28% | -283.76% | -244.64% | 15.14% | -155.13% | |
| D&A For EBITDA | 10 | 10 | 8 | 6 | 4 | 3 | |
| EBIT | -375 | -310 | -340 | -280 | 54 | -124 | |
| EBIT Margin | -156.25% | -120.15% | -290.60% | -250.00% | 14.10% | -158.97% | |
| Effective Tax Rate | - | - | - | - | 3.64% | - | |
| Revenue as Reported | 240 | 258 | 117 | 112 | 383 | 78 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.